Dallas, Texas – November 15, 2023 – Fletcher Spaght & Associates (“FSA”) a leading biopharma consulting firmed firm based in Boston, MA, has been retained by LexaGene Life Sciences, LLC (“LexaGene”) since early 2023 to provide ongoing consulting support and services to LexaGene. Throughout this ongoing engagement FSA has been in detailed discussions with the two large biopharma companies that purchased MiQLab® Systems to perform initial feasibility studies in the high-risk area of contamination during the biopharma manufacturing process. These two manufacturers, along with other well-known biopharma manufacturers, remain engaged in pursuing the development of our 2nd generation technology which will better address their unmet needs. In the veterinary-related biopharma space, LexaGene has engaged in detailed discussions with one of the largest firms and will continue to pursue a formal arrangement with the company.
For more information about LexaGene and the MiQLab System, please visit www.lexagenelifesciences.com
LexaGene Life Sciences, LLC
LexaGene is a molecular diagnostics company that has commercialized the MiQLab System for fast and easy detection of biological contaminants, pathogens and other molecular markers. The System is designed for on-site usage and uses real-time PCR chemistry.